Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase NA 2

Status

Recruiting 2Terminated 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Breast Neoplasms 580Neoplasms 487Prostatic Neoplasms 311Lung Neoplasms 238Colorectal Neoplasms 201Motor Activity 131Carcinoma, Non-Small-Cell Lung 117Uterine Cervical Neoplasms 112Brain Neoplasms 110Pancreatic Neoplasms 108Head and Neck Neoplasms 106Stomach Neoplasms 99Carcinoma, Hepatocellular 99Rectal Neoplasms 97Ovarian Neoplasms 86Colonic Neoplasms 86Neoplasm Metastasis 67Multiple Myeloma 65Esophageal Neoplasms 65Hematologic Neoplasms 61Urinary Bladder Neoplasms 60Glioblastoma 59Melanoma 58Sarcoma 57Precursor Cell Lymphoblastic Leukemia-Lymphoma 57Endometrial Neoplasms 56Glioma 53Lymphoma 50Leukemia, Myeloid, Acute 48Gastrointestinal Neoplasms 48

Interventions

Radiotherapy 2Immune Checkpoint Inhibitors 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase NA × Recruiting × Advanced NSCLC × Clear all
NCT06752044 2024-12-30

Neoantigen-based Peptide Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After First-line Treatment

The First Affiliated Hospital of Nanchang University

Phase NA Recruiting
10 enrolled
Thoracic

Advanced NSCLC

NCT06752057 2024-12-30

Neoantigen-loaded DC Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After First-line Treatment

The First Affiliated Hospital of Nanchang University

Phase NA Recruiting
10 enrolled
Thoracic

Advanced NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡